Salute e Benessere

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat…

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patientsOK-101 is the first IND granted by FDA to treat patients with NCP LONDON and NEW YORK, Oct.23, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
Nasdaq GlobeNewswire
23/10/2024

KFSHRC's Patient Flow & Capacity Command Centre: a Model of Smart Healthcare…

Predicting Healthcare Demand RIYADH, Saudi Arabia, Oct.23, 2024(GLOBE NEWSWIRE) -- World-class medical institutions are striving to find sustainable health innovations to maintain top healthcare services, address operational challenges, and manage potential crises. The Patient Flow & Capacity Command Centre at King Faisal Specialist Hospital & Research Centre (KFSHRC) serves as a leading model in enabling AI-driven healthcare management. Through Big Data analysis, these...
Nasdaq GlobeNewswire
23/10/2024

World's first aptamer-based histochemistry staining kit for HPV launched by…

This aptamer-based solution offers both better performance and lower cost alternative to similar antibody-based products. Constructed from oligonucleotides, aptamers are well-known to be more stable and consistent than animal-derived antibodies. They are also less temperature-sensitive and hence easier to transport, handle and store at normal room temperature. This aptamer-based solution offers both better performance and lower cost alternative to similar antibody-based products. Constructed...
PR Newswire
23/10/2024

General Silicones Debuts Compo-SiL® for Membrane Keypads in Europe

To book a meeting with General Silicones experts at either MEDICA or Electronica, please contact: [email protected] To book a meeting with General Silicones experts at either MEDICA or Electronica, please contact: [email protected] Trade show information: MEDICA: Düsseldorf,Germany Nov. 11-14, 2024 Hall 16, Booth: E14-5 Electronica: Munich, Germany Nov. 12-15, 2024 Hall A2, Booth: 456-3 "As devices flourish and diversify, membrane keypads are becoming a...
PR Newswire
23/10/2024

Smart Immune Announces Recommended SMART101 Dose for Adult Cancer…

ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is startingNo dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both hematological and solid tumorsParis, France – October 23, 2024– Smart Immune, a clinical-stage biotechnology company pioneering ProTcell, a thymus-empowered T-cell progenitor therapy platform, today announced that the recommended dose for its lead candidate, SMART101, has been established...
Nasdaq GlobeNewswire
23/10/2024

Ipsen delivers strong sales momentum in the first nine months of 2024 and…

PARIS, FRANCE, 23 October 2024- Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024YTD 2023% changeQ32024Q32023% change€m€mActualCER 1 €m€mActualCER 1 Oncology1 829,81 744,14,9%5,8%604,0574,5 ...
Nasdaq GlobeNewswire
23/10/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche's strong sales growth of 9%…

Group salesgrew by 6% 1at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8%In the third quarter, Group sales rose by 9% (6% in CHF), as they did in the second quarterPharmaceuticals Divisionsales rose by 7% in the first nine months; the strong growth of 9% in thebase business2was driven by continued high demand for our newer...
Nasdaq GlobeNewswire
23/10/2024

Press release: SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP…

SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORSGhent, Belgium, 23 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it obtained additional unsecured subordinated convertible bridge loans for a principal amount of EUR 0.5 million, with an additional tranche of…
Nasdaq GlobeNewswire
23/10/2024

TraceLink's New Singapore Office Fuels Expansion and Operational Excellence in…

The opening of the new Singapore office not only serves as a testament to TraceLink's success but also underscores its dedication to providing unparalleled support and services. The new office will serve as a center for TraceLink's operations in the region, enabling closer collaboration with customers and partners. The location, in the heart of Singapore's business district, positions the company to continue growing its talented team in an area that is central to its long-term strategy. The...
PR Newswire
23/10/2024

H&M Foundation: Global Change Award 2025 launched - with a mission to accelerate…

GCA is now seeking innovative ideas addressing different high emission areas across the textile industry value chain, including sustainable materials and processes, responsible production, mindful consumption, and 'wildcards' that support the GCA purpose. Today, only a fraction of philanthropic capital is directed to climate. "The textile industry needs all hands-on deck if we are going to meet our climate goals by 2050, and we must ensure this transition is fair for everyone...
PR Newswire
23/10/2024

JAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight…

Key Takeaways from the JAK Inhibitors Pipeline Report Key Takeaways from the JAK Inhibitors Pipeline Report Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment...
PR Newswire
22/10/2024

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the…

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q...
Nasdaq GlobeNewswire
22/10/2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after...
Nasdaq GlobeNewswire
22/10/2024

Sky Medical Technology Ltd Welcomes Publication of Compelling Evidence…

Key findings from the study, published in the International Wound Journal (IWJ), demonstrate that the geko device significantly enhances treatment outcomes by stimulating the common peroneal nerve, which increases venous, arterial, and microvascular blood flow. This physiological benefit translates into a remarkable 68% increase in wound healing compared to SoC alone. Key findings from the study, published in the International Wound Journal (IWJ), demonstrate that the geko device…
PR Newswire
22/10/2024

SAFE - Follow-up to the Paris Commercial Court hearing of October 18, 2024

Follow-up to the Paris Commercial Court hearing of October 18, 2024Fleurieux-sur-l'Arbresle-France – October 22, 2024, 8.15 p.m.As part of the Paris Commercial Court's hearing on October 18, 2024 to present the recovery plans for Safe SA and its subsidiaries (Safe Orthopaedics and Safe Medical), the Safe Group, which specializes in the design, manufacture and marketing of medical devices for spinal surgery, was notified of a favorable opinion by the procedural bodies, which will be...
Nasdaq GlobeNewswire
22/10/2024

Creative Innovation & Investment Shine On Day Two of Global Health Exhibition in…

In addition, panel discussions addressed key topics, such as the future of oncology, early detection and advanced therapies, cardiovascular disease, cyber-security in healthcare, and the evolving investment environment. In addition, panel discussions addressed key topics, such as the future of oncology, early detection and advanced therapies, cardiovascular disease, cyber-security in healthcare, and the evolving investment environment. "Early diagnosis saves lives," saidDr.Danuta...
PR Newswire
22/10/2024

KFSHRC Celebrates 40 Years of Stem Cell Leadership at GHE 2024

7,400+ Stem Cell Transplants Performed RIYADH, Saudi Arabia, Oct.22, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) celebrated the 40th anniversary of its Stem Cell program, a regional leader in bone marrow and stem cell transplantation. Ranked within the top 2% facilities worldwide for the volume of annual stem cell transplants, the Centre had successfully performed more than 7,400 transplants, 38% of which for pediatric patients. The achievement...
Nasdaq GlobeNewswire
22/10/2024

Gatemore Capital Management presents Watches of Switzerland Group at 13D Monitor

In September 2024, when WOSG was trading at 380p, Gatemore wrote a letter to the Board of WOSG to highlight the gap between the Company's strong intrinsic value and relatively weak share price, calling for the Company to launch a substantial share buyback to accrete permanent value for shareholders. InSeptember 2024, when WOSG was trading at 380p, Gatemore wrote aletterto the Board of WOSG to highlight the gap between the Company's strong intrinsic value and relatively weak share price,...
PR Newswire
22/10/2024

Schwarzkopf Professional Names Tracey Cunningham as U.S. Creative Director of…

Cunningham and Schwartz are the perfect additions to the Schwarzkopf Professional family as the brand grows its network of ambassadors. Last year, Schwarzkopf tapped Chris Appleton, one of Hollywood's most in-demand stylists, as a Schwarzkopf Global Color Ambassador further defining its presence in the U.S. celebrity conversation. "Tracey and Jacob are synonymous with servicing the Hollywood elite and forever being on the forefront of fashion-forward hair trends. Their commitment to color…
PR Newswire
22/10/2024

Spineway generates great interest at the EUROSPINE 2024 Congress in Vienna

Press release Ecully, October 22, 2024 – 6 p.m. Spineway generates great interestat the EUROSPINE 2024 Congress in Vienna The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, took part in theEUROSPINE 2024 Congress, Europe's leading spine conference, held from October 2 to 4, in Vienna, Austria.During the event, which brought together more than 3,500 spine surgeons and professionals from all over the world, Spineway...
Nasdaq GlobeNewswire
22/10/2024

AIMed 2024: A Pioneer in Healthcare Innovation to Join Key AI in Medicine Event

AIMed 2024 is the premier global event for artificial intelligence in healthcare, providing an ideal platform for industry experts like Reenita Das to share insights on leveraging AI to enhance healthcare systems and transform clinical workflows. Attendees will benefit from keynote speeches, hands-on workshops, and networking opportunities with top professionals worldwide. AIMed 2024 is the premier global event for artificial intelligence in healthcare, providing an ideal platform for…
PR Newswire
22/10/2024

ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40…

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Ottobock, a global player in the fields of prosthetics,...
Nasdaq GlobeNewswire
22/10/2024

Closing of acquisition of Ovizio Imaging Systems SA

ANNOUNCEMENT NO. 281 22 October 2024 Closing of acquisition of Ovizio Imaging Systems SAAll capital owners have now accepted ChemoMetec's takeover offer, and closing has been completed today and thus the final acquisition of 100% of the capital in the Belgian company Ovizio Imaging Systems SA for the previously announced purchase price of EUR 2,830,000.Additional information Martin Helbo Behrens, CEO Tel.: (+45) 48 13 10 20Kim Nicolajsen, CFO Tel.: (+45) 48 13 10 20 About...
Nasdaq GlobeNewswire
22/10/2024

KFSHRC Celebrates 28 Scientists Featured in Stanford's List of the Top 2% of…

With a large attendance of health leaders and experts from around the worldRIYADH, Saudi Arabia, Oct.22, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) celebrated the recognition of 28 of its scientists in Stanford University's list of the top 2% of the most-cited researchers globally across various disciplines over the past year. This event, attended by a significant number of health leaders and experts from around the world, took place at...
Nasdaq GlobeNewswire
22/10/2024
Altri  Comunicati